<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201310025181N11</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-10-15</date_registration>
      <primary_sponsor>Vice Chancellor for Research of School Medicine ,Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of pregnancy outcomes in two embryo transfer in IVF</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of pregnancy outcomes in two ways in the early stages of transition and transfer of Blastocyst in IVF  in Asr Hospital.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/5555</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>3</phase>
      <hc_freetext>Female infertility associated with anovulation.</hc_freetext>
      <i_freetext>Intervention 1: 21 cycles of agonists, GnRH 500 mcg subcutaneously Will continue until the day of HCG injection. And the next cycle of 2-3 days Gonadotropin 150 IU is injected . Based on ovarian response, the drug dose is increased . And the size of the follicle reaches 18-20 mm, HCG injections are administered at a dose of 10,000 units. 36 hours after the eggs have been taken AND  IVF with using sperm with  eggs are fertilized  In the second or  control group at the blastocyst stage (5 days) is passed. Intervention 2: 21 cycles of agonists, GnRH 500 mcg subcutaneously Will continue until the day of HCG injection. And the next cycle of 2-3 days Gonadotropin 150 IU is injected . Based on ovarian response, the drug dose is increased . And the size of the follicle reaches 18-20 mm, HCG injections are administered at a dose of 10,000 units. 36 hours after the eggs have been taken AND  IVF with using sperm with  eggs are fertilized . in the first group or the intervention early cleavage stage or 2-3 day old embryos  are transferred and.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahrokh Tehraninejad Ensieh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Immam Khomeini Hospital , vali-Asr Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6693 9320</telephone>
        <email>tehraninejadensi@yahoo.com</email>
        <affiliation>Vali-e-Asr reproductive HealthnResearch center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Rashidi Batool</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>vali-Asr Reproductive Health Research Center, Vali-Asr Hospital.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14194</zip>
        <telephone>+98 21 6693 9320</telephone>
        <email>bhrashidi@yahoo.com</email>
        <affiliation>Vali-asr Reoroductive Health Research Center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>I nclusion criteria :women  with age  20-40  years؛ Embryo transfer with IVF failuremore than twice. &#13;
Exclusion Criteria:Age more than 40 years ؛  Untreated women with uterine disorders؛   male  infertility.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility associated with anovulation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>21 cycles of agonists, GnRH 500 mcg subcutaneously Will continue until the day of HCG injection. And the next cycle of 2-3 days Gonadotropin 150 IU is injected . Based on ovarian response, the drug dose is increased . And the size of the follicle reaches 18-20 mm, HCG injections are administered at a dose of 10,000 units. 36 hours after the eggs have been taken AND  IVF with using sperm with  eggs are fertilized  In the second or  control group at the blastocyst stage (5 days) is passed.</i_keyword>
      <i_keyword>21 cycles of agonists, GnRH 500 mcg subcutaneously Will continue until the day of HCG injection. And the next cycle of 2-3 days Gonadotropin 150 IU is injected . Based on ovarian response, the drug dose is increased . And the size of the follicle reaches 18-20 mm, HCG injections are administered at a dose of 10,000 units. 36 hours after the eggs have been taken AND  IVF with using sperm with  eggs are fertilized . in the first group or the intervention early cleavage stage or 2-3 day old embryos  are transferred and</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Clinical pregnancy. Timepoint: 4 weeks after embryo transfer. Method of measurement: sonography.</prim_outcome>
      <prim_outcome>Twin pregnancy. Timepoint: 4 weeks after embryo transfer. Method of measurement: Sonography.</prim_outcome>
      <prim_outcome>Abortion. Timepoint: after positive pregnancy test. Method of measurement: Sonography.</prim_outcome>
      <prim_outcome>Chemical pregnancy. Timepoint: two  weeks after pregnancy. Method of measurement: blood test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>NO of embryo transfered. Timepoint: in the transfering the embryo. Method of measurement: Embryolog specialist.</sec_outcome>
      <sec_outcome>No of fertilized oocyte. Timepoint: Second day of fertilization Until the embryo transfer. Method of measurement: Embryologists recognized under microscope.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research of School Medicine ,Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-09-23</approval_date>
        <contact_name>School of Medicine, Tehran University of Medical Sciences</contact_name>
        <contact_address>School ofMedicine,Ghods Street,Keshavarz BLVD Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
